Sienna Biopharmaceuticals Return on Equity

Sienna Biopharmaceuticals (SNNAQ) currently reports a ROE of -207.4%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Sienna Biopharmaceuticals's ROE history and peer comparisons.

Sienna Biopharmaceuticals's ROE of -207.4% is lower than the Healthcare sector average of 22.76%. That is roughly 1011.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sienna Biopharmaceuticals's current -207.4% should be judged against Healthcare norms (sector average: 22.76%) and against SNNAQ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -207.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Sienna Biopharmaceuticals, and consider following SNNAQ for alerts when major investors trade the stock.

Sienna Biopharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -207.4% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SNNAQ with unrelated industries.